Company news

Femasys Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Femasys Inc. Regains Compliance with Nasdaq Listing Requirements

October 10, 2023

Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine

October 3, 2023

Femasys Inc. MDSAP Surveillance Audit Successfully Completed

October 2, 2023

Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate

September 26, 2023

Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution

September 24, 2023

Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control

September 19, 2023

Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September 5, 2023

Femasys Inc. Obtains Medical Device Establishment License from Health Canada

August 30, 2023

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update

August 9, 2023

Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc

August 2, 2023

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control

July 26, 2023

Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women

June 25, 2023

Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences

June 14, 2023

Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

June 13, 2023

Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada

June 7, 2023

Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting

May 10, 2023

Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023

May 10, 2023

Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

April 18, 2023

Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada

April 17, 2023

Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update

March 29, 2023

Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device

December 18, 2022

Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design

November 28, 2022

Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update

November 9, 2022

Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement

October 19, 2022

Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs

October 11, 2022

Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control

October 5, 2022

Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team

September 28, 2022

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update

August 9, 2022

Femasys Inc. Announces Existing Board Member Charles Larsen as Chairperson of the Board

July 5, 2022

Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2022

May 10, 2022

Femasys Inc. Announces Financial Results for the Year Ended December 31, 2021

March 23, 2022

Femasys Inc. Announces the Appointment of Dov Elefant to New Position of Chief Financial Officer

February 23, 2022

Femasys Inc. Announces the Appointment of Wendy Perrow, Transformational Biotech Entrepreneur, as New Board Member

January 19, 2022

Femasys Inc. Announces Financial Results for the Third Quarter of 2021

November 9, 2021

Femasys Inc. Announces the Appointment of Edward Evantash, M.D. as Chief Medical Officer

August 31, 2021

Femasys Inc. Announces Financial Results for the Second Quarter of 2021

August 10, 2021

Femasys Inc. Announces First Patient Treated in Pivotal Trial for FemaSeed

July 19, 2021

← Newer news releases

Decks

The 5 newest of 14 decks. Every deck is listed under its year.